Tango Therapeutics, Inc. business relationships
Companies named in Tango Therapeutics, Inc.’s 10-K filed 2026-03-05, and public companies whose annual reports name Tango Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.2 / 10
- AI naming
- 46 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in Tango Therapeutics, Inc.’s annual report 10
“There was no financial penalty to the Company as a result, no licensed programs were returned to the Company, all ongoing work at Gilead on licensed programs will continue and agreements for all future milestones and royalties remain in effect.” SEC filing
“In August 2020, the Company and Gilead entered into an Amended Research Collaboration and License Agreement (the Gilead Agreement), which superseded and replaced the 2018 Gilead Agreement.” SEC filing
“costs to fulfill our obligations under the collaboration with Gilead through August 2025;” SEC filing
“We have a clinical collaboration agreement with Eli Lilly and Company, or Lilly, that will supply Verzenio ® (abemaciclib), a CDK4/6 inhibitor, for use in combination with TNG456 in our ongoing Phase 1/2 clinical trial focused on MTAP-deleted GBM.” SEC filing
“We have entered into separate clinical collaboration and supply agreements with RevMed, Lilly, and Erasca, under which we plan to conduct combination clinical trials with RevMed's RAS(ON) multi- and G12D-selective inhibitors, Lilly's abemaciclib and Erasca's pan-RAS molecular glue, respectively.” SEC filing
“The loss of any of these suppliers, including WuXi AppTec, could significantly harm our business.” SEC filing
“In March 2020, the Company entered into a License Agreement (the Medivir Agreement) with Medivir AB (Medivir), pursuant to which the Company obtained an exclusive license to all patents, know-how and other intellectual property associated with a preclinical-stage research program.” SEC filing
“...imetostat enabling the potential for efficacious and tolerable RAS inhibitor combinations, in March 2026, we entered into a clinical trial collaboration and supply agreement (CTCSA) with Erasca, Inc., or Erasca, to evaluate vopimetostat in combination with Erasca's pan-RAS molecular glue, ERAS-0015.” SEC filing
“We have an ongoing clinical collaboration with Revolution Medicines, Inc., or RevMed, and are currently combining vopimetostat with daraxonrasib, a RAS(ON) multi-selective inhibitor, and separately with zoldonrasib, a RAS(ON) G12D-selective inhibitor, in MTAP-deleted, RAS-mutant pancreatic and lung...” SEC filing
“the potential benefits of strategic collaboration agreements (including our clinical trial and supply agreements with Revolution Medicines, Inc. and Erasca, Inc.), our ability to enter into strategic collaborations or arrangements, and our ability to attract collaborators with development, regulator...” SEC filing
Companies whose annual reports name Tango Therapeutics, Inc. 2
“In addition, we have entered into a clinical trial collaboration and supply agreement (CTCSA) with Tango Therapeutics, Inc. (Tango) to enable the evaluation of ERAS-0015 with Tango's PRMT5 inhibitor, vopimetostat, in a Phase 1 clinical trial sponsored by Tango.” SEC filing
“In November 2024, we entered into a clinical collaboration with Tango Therapeutics, Inc. (Tango) pursuant to which Tango is evaluating its compound vopimetostat (TNG462), an MTA-cooperative PRMT5 inhibitor, in combination with daraxonrasib or zoldonrasib in patients with MTAP-depleted, RAS mutant PD...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.